418 related articles for article (PubMed ID: 33806604)
1. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria.
Yusuf E; Bax HI; Verkaik NJ; van Westreenen M
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33806604
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales.
Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L
Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303
[TBL] [Abstract][Full Text] [Related]
4. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
Bader MS; Loeb M; Leto D; Brooks AA
Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
[TBL] [Abstract][Full Text] [Related]
5. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
6. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
7. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
[TBL] [Abstract][Full Text] [Related]
8. New antibiotics for Gram-negative pneumonia.
Bassetti M; Magnè F; Giacobbe DR; Bini L; Vena A
Eur Respir Rev; 2022 Dec; 31(166):. PubMed ID: 36543346
[TBL] [Abstract][Full Text] [Related]
9. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.
Barbier F; Hraiech S; Kernéis S; Veluppillai N; Pajot O; Poissy J; Roux D; Zahar JR;
Ann Intensive Care; 2023 Jul; 13(1):65. PubMed ID: 37462830
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Danjean M; Hobson CA; Gits-Muselli M; Courroux C; Monjault A; Bonacorsi S; Birgy A
Clin Microbiol Infect; 2022 Nov; 28(11):1503.e1-1503.e3. PubMed ID: 35777602
[TBL] [Abstract][Full Text] [Related]
11. Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals : A Retrospective Cohort Study.
Strich JR; Mishuk A; Diao G; Lawandi A; Li W; Demirkale CY; Babiker A; Mancera A; Swihart BJ; Walker M; Yek C; Neupane M; De Jonge N; Warner S; Kadri SS;
Ann Intern Med; 2024 May; 177(5):559-572. PubMed ID: 38639548
[TBL] [Abstract][Full Text] [Related]
12. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Liscio JL; Mahoney MV; Hirsch EB
Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
[TBL] [Abstract][Full Text] [Related]
13. New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives.
Karvouniaris M; Pontikis K; Nitsotolis T; Poulakou G
Expert Rev Anti Infect Ther; 2021 Jul; 19(7):825-844. PubMed ID: 33270485
[No Abstract] [Full Text] [Related]
14. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
Shirley M
Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.
Rodríguez-Baño J; Gutiérrez-Gutiérrez B; Machuca I; Pascual A
Clin Microbiol Rev; 2018 Apr; 31(2):. PubMed ID: 29444952
[TBL] [Abstract][Full Text] [Related]
16. New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.
Bassetti M; Mularoni A; Giacobbe DR; Castaldo N; Vena A
Semin Respir Crit Care Med; 2022 Apr; 43(2):280-294. PubMed ID: 35088403
[TBL] [Abstract][Full Text] [Related]
17. New antibiotics for ventilator-associated pneumonia.
Bassetti M; Vena A; Castaldo N; Righi E; Peghin M
Curr Opin Infect Dis; 2018 Apr; 31(2):177-186. PubMed ID: 29337703
[TBL] [Abstract][Full Text] [Related]
18. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
19. Infections Caused by Carbapenem-Resistant
Sheu CC; Chang YT; Lin SY; Chen YH; Hsueh PR
Front Microbiol; 2019; 10():80. PubMed ID: 30761114
[TBL] [Abstract][Full Text] [Related]
20. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance.
Syue LS; Chen YH; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2016 Apr; 47(4):250-8. PubMed ID: 27005457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]